research Adalimumab-related alopecia in a patient affected by psoriasis
Adalimumab can cause hair loss and scalp issues in some psoriasis patients.
Search
for
Sort by
Research
120-150 / 1000+ resultsresearch Folliculitis decalvans managed with adalimumab: A case report
Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.
research Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
research Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.
research P368 Rare skin disorders in IBD patients treated with anti-TNFs
Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
research 224 Humoral immune response to COVID-19 vaccination in psoriasis patients on biologic therapy is impaired compared to healthy controls
Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
research Infliximab as First‐Line Therapy in Severe Pediatric Crohn Disease
Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.
research Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis
Mycophenolate mofetil can effectively treat autoimmune hepatitis when standard drugs fail.
research USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
research Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
Blocking IL-8 can reduce skin rashes from cancer treatment.
research A Case of Idiopathic Follicular Mucinosis Treated Successfully with Cyclosporine.
Cyclosporine effectively treated a woman's stubborn skin condition.
research POS0548 ACUTE AND SUBACUTE SKIN MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS ARE ASSOCIATED WITH AN EARLIER RESPONSE TO BELIMUMAB THAN THE CHRONIC PHENOTYPE: PRELIMINARY DATA FROM THE NEW NATION-WIDE COHORT OF BELIMUMAB IN REAL LIFE SETTING STUDY—NEW JOINT AND SKIN (BERLISS-NEJS)
Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.
research Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata
research Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report
A rash from semaglutide may be due to propylene glycol, not the drug itself.
research SAT0200 UNUSUAL SYSTEMIC LUPUS ERYTHEMATOSUS/SJOEGREN'S SYNDROME PHENOTYPE IN A PATIENT WITH A TNFAIP3 GENE MUTATION
A TNFAIP3 gene mutation can cause unusual and varied symptoms of lupus and Sjogren's syndrome.
research Tebentafusp-tebn (Kimmtra®)
Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
research POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
Tofacitinib is a promising treatment for children with rheumatic diseases.
research Interventions for morphea
Some treatments like methotrexate with prednisone might help juvenile morphea, but more research is needed to confirm.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research New drugs: Agalsidase alfa
Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
research 151 High effectiveness of tildrakizumab over 52 weeks in patients with or without nail psoriasis: results from the phase IV POSITIVE Austrian subset
Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
research ANIFROLUMAB IN THE MANAGEMENT OF LUPUS HEADACHES: A CASE REPORT
Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.
research Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study
Omalizumab is generally safe for chronic urticaria, but hair loss is a common side effect.
research Case report: pemphigus vulgaris in an adolescent
An 18-year-old girl with pemphigus vulgaris needed strong medication and careful treatment due to ineffective initial therapies and side effects.
research 0196 Levamisole-induced pyoderma gangrenosum case report
research Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
Dupilumab helped a 4-year-old grow hair back after another treatment failed.
research Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation
The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
research The Future of Systemic Lupus Erythematosus Treatment: The Promise of Selective Immunotherapies, Anifrolumab and Belimumab, Compared to Blanket Immunosuppressives
Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.
research Clinical evaluation of efficacy of Majoon Ushba and Marham Gulabi in Qooba (Dermatophytosis)
Majoon Ushba and Marham Gulabi effectively treat dermatophytosis.